{"id":"W3131966309","doi":"10.1038/s41598-021-82671-w","title":"A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"PharmaMar; AstraZeneca España; AstraZeneca","keywords":"Olaparib; Medicine; Neutropenia; Tolerability; Internal medicine; Oncology; Pharmacokinetics; PARP inhibitor; Nausea; Adverse effect; Gastroenterology; Pharmacology; Chemotherapy; Poly ADP ribose polymerase; Polymerase; Biology; Genetics; DNA","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001393165,0.001139774,0.002458462,0.0004760587,0.0004016225,0.0009500209,0.0005643137,0.0009359978,0.00143265],"category_scores_gemma":[0.00142565,0.0006919282,0.001060054,0.0005615577,0.000772638,0.0007119865,0.0002965802,0.002509599,0.0005117549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009800227,"about_ca_system_score_gemma":0.001204638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005347601,"about_ca_topic_score_gemma":0.0007422864,"domain_scores_codex":[0.9992422,0.000405637,0.00003467276,0.0001337034,0.0000777258,0.0001060416],"domain_scores_gemma":[0.999084,0.000186987,0.0001569425,0.00009994936,0.00005916768,0.0004129473],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5234078,0.1391493,0.02701878,0.0006154239,0.001498535,0.0009906125,0.0008202283,0.00801313,0.1529707,0.0004981046,0.00313545,0.141882],"study_design_scores_gemma":[0.225917,0.7382159,0.0202043,0.00001938455,0.0003591515,0.0007562843,0.00009485948,0.003466833,0.007883615,0.0002340786,0.002802944,0.00004566887],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970896,0.0007212787,0.0004699929,0.0001699633,0.00003476288,0.0007065209,0.0002922364,0.00003807367,0.0004777217],"genre_scores_gemma":[0.9948107,0.0004866156,0.001616642,0.0003600267,0.00007323474,0.000939852,0.0008886217,0.00001842181,0.0008058023],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002458462,"threshold_uncertainty_score":0.007367849,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01939617000832062,"score_gpt":0.3313120006591224,"score_spread":0.3119158306508018,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}